EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies

Diabetes mellitus als Risikofaktor für Pneumokokkenerkrankungen und schwere Folgeergebnisse sowie Wirksamkeit/Effektivität der Impfung bei Diabetes: Ergebnisse einer Metaanalyse Beobachtungsstudien

Giovanni Antonio Silverii, Giovanni Gabutti, Silvio Tafuri, Francesca Sarti, Anna Pratesi, Alessandra Clerico, Riccardo Fornengo, Carla Greco, Concetta Irace, Valeria Sordi, Gian Pio Sorice, Massimiliano Cavallo und 4 weitere

Acta Diabetologica · 29.04.2024 · 61 (8) · 1029-1039

DOI: 10.1007/s00592-024-02282-5 ↗

Auf einen Blick

Menschen mit Diabetes mellitus hatten ein höheres Risiko für Pneumokokkenerkrankungen und ungünstige Verläufe. Für einzelne Impfoutcomes zeigten sich in den eingeschlossenen Studien teils niedrigere Raten.

Fragestellung

Welchen Einfluss hat Diabetes mellitus auf das Risiko für Pneumokokkenerkrankungen und wie wirksam sind Impfungen bei Menschen mit Diabetes?

Methode

Zwei systematische Suchen in MEDLINE, Cochrane, ClinicalTrials.gov und EMBASE bis 1. Juni 2023; eingeschlossen wurden Beobachtungsstudien und randomisierte klinische Studien beim Menschen.

Ergebnisse

36 Beobachtungsstudien zu Risiko und Komplikationen; 11 Studien zur Impfwirksamkeit/-effektivität (1 RCT, 10 Beobachtungsstudien). Höheres Risiko bei DM: IPD OR 2,42 [2,00; 2,92], CFR OR 1,61 [1,25; 2,07], Pneumokokkenpneumonie OR 2,98 [2,76; 3,22], ICU-Aufnahme OR 2,09 [1,20; 3,66].

Schlussfolgerung der Autor:innen

Menschen mit Diabetes mellitus haben ein höheres Risiko für einen ungünstigeren Verlauf von Pneumokokkenerkrankungen und sollten in Impfkampagnen gezielt berücksichtigt werden; für Impfoutcomes bei Diabetes braucht es mehr Evidenz.

Kernaussagen

  • DM war mit höherem Risiko für invasive Pneumokokkenerkrankung verbunden.
  • Auch Fallsterblichkeit, Pneumokokkenpneumonie und ICU-Aufnahme waren erhöht.
  • Einige Impfoutcomes waren günstiger, aber nur für einzelne Endpunkte.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Acta Diabetologica, online erschienen am 29.04.2024. Verfasst von Giovanni Antonio Silverii und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50139, Florence, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Pneumococcal Infections, Pneumococcal Vaccines, Vaccination. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Firenze.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To collect all available evidence on the effect of diabetes mellitus (DM) as a risk factor for pneumococcal disease incidence and related complications, and on the efficacy/effectiveness of vaccines in patients with DM.

Methods

Two distinct systematic searches on MEDLINE, Cochrane, ClinicalTrials.gov and EMBASE databases were performed, one for each meta-analysis, collecting all observational (cohort and case–control) studies and randomized clinical trials performed on humans up to June 1st, 2023.

Results

We retrieved 36 observational studies comparing risk for pneumococcal disease and related complications in people with or without DM, and 11 studies (1 randomized clinical trial and 10 observational studies) assessing conjugated and polysaccaridic vaccines efficacy/effectiveness on preventing such outcomes. People with DM were at higher risk for Invasive Pneumococcal Disease (unadjusted OR 2.42 [2.00; 2.92]); Case-Fatality Rate (unadjusted OR 1.61 [1.25; 2.07], Pneumococcal pneumonia (unadjusted OR 2.98 [2.76; 3.22), and Intensive care unit admission for pneumococcal disease (unadjusted OR 2.09 [1.20; 3.66]). In diabetic individuals vaccinated with conjugated vaccine, incidence of pneumonia specific for vaccine type in a clinical trial (OR 0.237 [0.008; 0.704]), and hospitalization for overall pneumonia during the year following the polysaccharide vaccination in observational studies (unadjusted OR 0.63 [0.45–0.89]) were significantly lower in comparison with unvaccinated DM subjects, with no significant differences for other outcomes.

Conclusions

People with diabetes mellitus are at higher risk for less favourable course of pneumococcal disease and should be therefore targeted in vaccination campaigns; more evidence needs to be collected on vaccination outcomes in people with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusPneumococcal InfectionsPneumococcal VaccinesVaccinationHumansDiabetes ComplicationsObservational Studies as TopicRisk FactorsVaccine Efficacy

Stichwörter der Autor:innen

Diabetes mellitusPneumococcal diseasePneumococcal vaccination

Substanzen

Pneumococcal Vaccines

Autor:innen und Institutionen

  • Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50139, Florence, Italy.
  • Coordinator Working Group "Vaccines and Immunization Policies", Italian Scientific Society of Hygiene, Preventive Medicine and Public Health (SItI), Terni, Italy.
  • Interdisciplinary Department of Medicine, Aldo Moro, University of Bari, Bari, Italy.
  • Diabetes Unit, Azienda Sanitaria Città di Torino, Turin, Italy.
  • Diabetes Unit, ASL TO4, Chivasso (Turin), Italy.
  • Biomedical and Metabolic Department, Modena and Reggio Emilia University, Modena, Italy.

Förderung

  • Università degli Studi di Firenze

Zitieren

APA

Silverii, G. A., Gabutti, G., Tafuri, S., Sarti, F., Pratesi, A., Clerico, A., Fornengo, R., Greco, C., Irace, C., Sordi, V., Sorice, G. P., Cavallo, M., Ponziani, M. C., Mannucci, E., Dicembrini, I., & SID-AMD-SItI Working Group on Diabetes, Vaccines (2024). Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies. Acta Diabetologica, 61(8), 1029-1039. https://doi.org/10.1007/s00592-024-02282-5

Vancouver

Silverii GA, Gabutti G, Tafuri S, Sarti F, Pratesi A, Clerico A, et al. Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies. Acta Diabetologica. 2024;61(8):1029-1039. doi:10.1007/s00592-024-02282-5

BibTeX
@article{Silverii2024,
  author = {Silverii, Giovanni Antonio and Gabutti, Giovanni and Tafuri, Silvio and Sarti, Francesca and Pratesi, Anna and Clerico, Alessandra and Fornengo, Riccardo and Greco, Carla and Irace, Concetta and Sordi, Valeria and Sorice, Gian Pio and Cavallo, Massimiliano and Ponziani, Maria Chantal and Mannucci, Edoardo and Dicembrini, Ilaria and SID-AMD-SItI Working Group on Diabetes, Vaccines, SID-AMD-SItI Working Group on Diabetes, Vaccines},
  title = {Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies},
  journal = {Acta Diabetologica},
  year = {2024},
  volume = {61},
  number = {8},
  pages = {1029--1039},
  doi = {10.1007/s00592-024-02282-5}
}
Kostenlos starten →